Equity Capital Markets
Equity Capital Markets Group
Industry-Leading Full-Service Equity Capital Markets Group
The Equity Capital Markets Group (ECM) is responsible for originating and executing public and private equity and equity linked offerings as well as SPACs. In 2021, the ECM group managed over 265 equity and equity-linked transactions, including executing 76 IPOs, raising more than $108B. In addition, the ECM team has a leading SPAC business, advising in 2021 on more than 45 transactions within all phases of the Special Purpose Acquisition Company (SPAC) lifecycle, including IPOs, PIPEs, and de-SPAC engagements. The Stifel equity platform brings differentiated institutional access and retail distribution in the US and Internationally.
Stifel is the Leading IPO Bookrunner Among All Middle-Market or Specialist Firms
Learn MoreNotable Transactions
$ 86,250,000,000
Co-Manager
IPO
Aerospace, Defense & Government Services
Jun 2026
$ 690,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Jun 2026
$ 200,200,000
Joint Lead Bookrunning Manager
IPO
Energy & Natural Resources
Jun 2026
$ 650,000,000
Joint Bookrunning Manager
IPO
Aerospace, Defense & Government Services
Jun 2026
Advisor to Buyer
Mergers & Acquisitions
Engineering & Construction, and Infrastructure
May 2026
$ 254,880,000
Joint Bookrunning Manager
Initial Public Offering
Biopharma
Apr 2026
$ 150,800,000
Joint Bookrunning Manager
Confidentially Marketed Follow-on Offering
Biopharma
Apr 2026
$ 191,250,000
Joint Bookrunning Manager
Initial Public Offering
Tools & Diagnostics
Apr 2026
$ 700,350,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Apr 2026
$ 117,500,000
Left Bookrunning Manager
Registered Direct
Biopharma
Apr 2026
$ 350,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Mar 2026
$ 719,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Mar 2026
$ 650,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Mar 2026
$213,037,500
Joint Bookrunning Manager
Follow-on Offering
Energy & Natural Resources
Mar 2026
$ 172,500,000
Joint Bookrunning Manager
Initial Public Offering
Biopharma
Feb 2026
$1,150,000,000
Joint Bookrunning Manager
Follow-on and Concurrent Tangible Equity Unit Offering
Aerospace, Defense & Government Services
Feb 2026
$175,000,012
Lead Left Bookrunning Manager
Confidentially Marketed Follow-on Offering
Aerospace, Defense & Government Services
Feb 2026
$ 150,000,000
Joint Bookrunning Manager
Confidentially Marketed Follow-on Offering
Biopharma
Feb 2026
$ 150,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Feb 2026
$ 230,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Feb 2026
$ 200,000,000
Joint Bookrunning Manager
Initial Public Offering
Energy & Natural Resources
Feb 2026
$692,300,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Dec 2025
$402,500,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Dec 2025
$241,500,000
Lead Left Bookrunning Manager
Initial Public Offering
Engineering & Construction, and Infrastructure
Dec 2025
$682,500,000
Joint Bookrunning Manager
IPO
Tech-Enabled Services
Oct 2025
$316,250,000
Joint Bookrunning Manager
Confidentially Marketed Follow-on Offering
Biopharma
Oct 2025
$135,000,000
Joint Bookrunning Manager
Confidentially Marketed Follow-on Offering
Biopharma
Oct 2025
$273,100,000
Joint Bookrunning Manager
IPO
Tools & Diagnostics
Oct 2025
$400,000,000
Joint Bookrunning Manager
Follow-On Offering
Aerospace, Defense & Government Services
Oct 2025
$135,000,000
Joint Bookrunning Manager
Confidentially Marketed Follow-on Offering
Biopharma
Oct 2025
$251,400,000
Joint Bookrunning Manager
Confidentially Marketed Follow-on Offering
Biopharma
Oct 2025
$287,500,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Sep 2025
$729,100,000
Joint Bookrunning Manager
IPO
Sep 2025
$115,000,000
Joint Bookrunning Manager
Confidentially Marketed Follow-on Offering
Biopharma
Sep 2025
$345,000,000
Joint Bookrunning Manager
Follow-On Offering
Biopharma
Sep 2025
$288,420,000
Joint Bookrunning Manager
Follow-On Offering
Biopharma
Sep 2025
$230,000,000
Joint Bookrunning Manager
Follow-on Offering
Aerospace, Defense & Government Services
Sep 2025
$728,000,000
Joint Bookrunning Manager
IPO
Engineering & Construction, and Infrastructure
Sep 2025
$338,235,280
Joint Bookrunning Manager
Initial Public Offering
Restaurants
Sep 2025
$110,400,000
Joint Bookrunning Manager
Initial Public Offering
Electronics & Industrial Technology
Jul 2025
$172,500,000
Sole Bookrunning Manager
Initial Public Offering
Jul 2025
$402,500,000
Joint Lead Bookrunning Manager
Follow-on Offering
Electronics & Industrial Technology
Jun 2025
$502,908,800
Joint Bookrunning Manager
Initial Public Offering
Healthcare Services
May 2025
$201,250,000
Sole Bookrunning Manager
Initial Public Offering
Internet & Digital Media
May 2025
$124,085,000
Lead Left Bookrunning Manager
Follow-on Offering
Aerospace, Defense & Government Services
May 2025
$175,000,000
Joint Bookrunner
Follow-on Offering
Biopharma
Mar 2025
$202,000,000
Joint Bookrunning Manager
Initial Public Offering
Medtech
Mar 2025
$250,000,000
Joint Bookrunner
Confidentially Marketed Follow-on Offering
Biopharma
Mar 2025
C$17,400,000
Sole Bookrunner
Follow-on Offering
Metals & Mining
Feb 2025
A$80,000,000
Joint Lead Arranger & Joint Bookrunner
Follow-on Offering
Energy & Natural Resources
Feb 2025
$384,000,000
Joint Bookrunner
Initial Public Offering
Building Products
Feb 2025
$219,200,000
Joint Bookrunner
Initial Public Offering
Biopharma
Feb 2025
$150,000,000
Joint Bookrunner
Follow-on Offering
Biopharma
Feb 2025
$230,000,000
Left Bookrunner
Follow-on Offering
Energy & Natural Resources
Feb 2025
$75,000,000
Joint Bookrunner
Follow-on Offering
Biopharma
Jan 2025
$50,000,000
Joint Bookrunner
Registered Direct
Biopharma
Dec 2024
$257,600,000
Joint Bookrunner
Follow-on Offering
Biopharma
Dec 2024
$624,800,000
Joint Bookrunner
Initial Public Offering
Software
Dec 2024
$402,500,000
Joint Bookrunner
Follow-on Offering
Biopharma
Dec 2024
$115,000,000
Joint Bookrunner
Confidentially Marketed Follow-on Offering
Aerospace, Defense & Government Services
Dec 2024
$196,956,533
Joint Bookrunner
Follow-on Offering
Energy & Natural Resources
Nov 2024
$152,500,000
Joint Bookrunner
Follow-on Offering
Aerospace, Defense & Government Services
Nov 2024
$60,000,000
Joint Bookrunner & Joint Placement Agent
Registered Direct & PIPE
Biopharma
Nov 2024
$172,499,859
Joint Bookrunner
Follow-on Offering
Aerospace, Defense & Government Services
Oct 2024
$94,500,000
Joint Bookrunner
Follow-on Offering
Real Estate
Sep 2024
$517,500,000
Joint Bookrunner
Follow-on Offering
Industrial & Environmental Services
Sep 2024
$575,000,000
Joint Bookrunner
Follow-on Offering
Biopharma
Sep 2024
$362,250,000
Joint Bookrunner
Initial Public Offering
Biopharma
Sep 2024
$187,680,000
Joint Bookrunner
Initial Public Offering
Biopharma
Sep 2024
$200,536,320
Joint Placement Agent
PIPE
Biopharma
Sep 2024
$258,750,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Sep 2024
$200,000,000
Joint Bookrunner
Follow-on Offering
Biopharma
Sep 2024
$152,173,925
Joint Bookrunner
Follow-on Offering
Energy & Natural Resources
Sep 2024
$220,000,000
Sole Bookrunner
Initial Public Offering
Business Services
Sep 2024
$137,000,000
Follow-on Offering
Energy & Natural Resources
Sep 2024
Currency volume represents full credit to each underwriter. All transaction announcements appear as a matter of record only. Stifel collectively refers to Stifel, Nicolaus & Company, Incorporated and other affiliated broker-dealer subsidiaries of Stifel Financial Corp.
Team
Seth Rubin
Head of Global Equity Capital Markets
San Francisco
Christophe Alleman
Managing Director
Paris
Brian Anderson
Managing Director, Equity Private Placements
Bethesda
Bill Bunting
Managing Director, Equity Private Placements
San Francisco
Lewis Chia
Managing Director
San Francisco
Ken Clausman
Managing Director
New York
Daniel J. Covatta
Head of U.S. Syndicate
Baltimore
Alysa Craig
Managing Director, Head of SPAC Banking
New York
Craig DeDomenico
Managing Director, Head of Equity-Linked Capital Markets
New York
Jerome Guyot
Managing Director
Paris
Pierre Kiecolt-Wahl
Managing Director
Paris
Cullen Lee
Managing Director, Head of Technology ECM
Nicholas Oust
Managing Director, Head of Healthcare ECM
San Francisco
Rosemary Teixeira
Managing Director, Head of ECM, Stifel Canada
Toronto
Paul Lequeux
Director
London
Jean De Pracomtal
Director
Paris
Brandon Roop
Director
Denver
Mark White
Director, Equity Capital Markets & Syndicate
Baltimore
